✦ LIBER ✦

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

✍ Scribed by Thomas Yau, Hilda Wong, Pierre Chan, T. J. Yao, R. Pang, T. T. Cheung, S. T. Fan, Ronnie T. Poon

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

AOSOP3 Combination of bevacizumab and er

✍ T. Yau; H. Wong; P. Chan; T.J. Yao; T.T. Cheung; S.T. Fan; R.T. Poon 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Phase 2 study of bevacizumab plus erloti

✍ Philip A. Philip; Michelle R. Mahoney; Kyle D. Holen; Donald W. Northfelt; Henry 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 825 KB

34 POSTER A phase II study of the combin

✍ M. Thomas; M. Lwasaki; K. Higginbotham; R. Lozano; K. Glover; J. Abbruzzese 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 365 KB

A phase I/II study of S-1 with sorafenib

✍ Ooka, Yoshihiko; Chiba, Tetsuhiro; Ogasawara, Sadahisa; Arai, Kuniaki; Suzuki, E 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 166 KB

Phase II study of sirolimus in treatment

✍ Thomas Decaens; Alain Luciani; Emmanuel Itti; Anne Hulin; Françoise Roudot-Thora 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 668 KB

Phase 2 Study of Combined Sorafenib and

✍ Chen, Shang-Wen; Lin, Li-Ching; Kuo, Yu-Cheng; Liang, Ji-An; Kuo, Chia-Chun; Chi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 489 KB